title: Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris.
abstract: We examined the effects of cilostazol on impaired coronary arterial responses in patients with vasospastic angina (VSA). Thirty patients who were diagnosed with VSA based on an acetylcholine provocation test and 10 subjects with normal coronary arteries were enrolled. The patients were divided into the following 3 groups: no antiplatelet agent treatment group, aspirin treatment, or cilostazol treatment groups. Coronary flow reserve (CFR), coronary flow volume at maximum hyperemia, and epicardial coronary artery diameter after administration of N(G)-monomethyl-L-arginine (L-NMMA) were examined using a Doppler flow wire before and 6 months after the start of this study. CFR, coronary flow volume at maximum hyperemia, and diameter changes by L-NMMA were significantly increased in the cilostazol treatment group compared with the other 2 groups. In conclusion, cilostazol increased CFR and flow-dependent coronary dilation; these changes were attributable to nitric oxide. Cilostazol may improve coronary vascular endothelial dysfunction and coronary hemodynamics in patients with VSA.
authors.affiliation: Department of Cardiology, Uwajima City Hospital, Uwajima, Japan. kawatana@uwajima-mh.go.jp
authors.forename: Kouki
authors.initials: K
authors.lastname: Watanabe
authors.forename: Shuntaro
authors.initials: S
authors.lastname: Ikeda
authors.forename: Jirou
authors.initials: J
authors.lastname: Komatsu
authors.forename: Shinji
authors.initials: S
authors.lastname: Inaba
authors.forename: Jun
authors.initials: J
authors.lastname: Suzuki
authors.forename: Shozo
authors.initials: S
authors.lastname: Sueda
authors.forename: Jun-ichi
authors.initials: J
authors.lastname: Funada
authors.forename: Masafumi
authors.initials: M
authors.lastname: Kitakaze
authors.forename: Michihito
authors.initials: M
authors.lastname: Sekiya
mesh_terms: D000787:Angina Pectoris / Q000188:drug therapy* / Q000503:physiopathology; D000077407:Cilostazol; D003326:Coronary Circulation / Q000187:drug effects; D004730:Endothelium, Vascular / Q000187:drug effects*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000627:therapeutic use; D011446:Prospective Studies; D013777:Tetrazoles / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D013777:Tetrazoles; D014665:Vasodilator Agents; D009569:Nitric Oxide; D000077407:Cilostazol